Biologics CDMO Market Segmentation:
Product Type Segment Analysis
The biologics segment is likely to capture biologics CDMO market share of around 73.4% by the end of 2035. The segment is growing due to increasing demand for advanced therapies such as monoclonal antibodies, vaccines, and gene therapies. As diseases such as cancer, autoimmune disorders, and chronic conditions rise, the need for recombinant products intensifies. CROs are crucial in providing exclusive processing services for these complex drugs, ensuring efficient formulation and compliance with regulatory standards. Additionally, the shift toward personalized medicine and biosimilars further drives growth, boosting the need for contract manufacturing capabilities in bio-med formulation.
Molecule Type Segment Analysis
By molecule type, the monoclonal antibodies segment is estimated to garner the majority biologics CDMO market share, over the forecast period. The segment’s growth is attributed to the increasing requisition for targeted therapies in treating cancer, autoimmune diseases, and other chronic conditions. According to NLM in June 2024, 56 anticancer monoclonal antibody-based treatments received approval from the Food and Drug Administration (FDA) and 48 from the European Medicines Agency (EMA). mAbs offer high specificity and efficacy, making them a preferred choice in modern medicine. They provide expertise, infrastructure, and compliance for large-scale mAb formation, driven by biotech advancements and growing global healthcare needs.
Our in-depth analysis of the global biologics CDMO market includes the following segments:
|
Product Type |
|
|
Molecule Type |
|
|
Type |
|
|
Indication |
|
